Conclusion
tumors, sarcomas
DUODENAL CARCINOMA, TUMORS, THYROID CARCINOMA, SARCOMAS
Regardless of whether the patients previously had received radiotherapy, immunotherapy or anti-angiogenic drugs, the patients progressing on multi-line therapy could still benefit from radiotherapy in combination with liposomal irinotecan, camrelizumab and anti-angiogenic. For rare tumors without prior systemic therapy (such as certain sarcomas, duodenal carcinoma, and ansplastic thyroid carcinoma), the efficacy of this therapy was better than the existing therapies.